Project Grant R44DK139877
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$740K
Awardee
Xylyx Bio, Inc. (N2N9KL2Y52X1)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Brooklyn, NY 11226, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support the development of a proteomic assay to monitor the success of regenerative medicine therapies involving cell replacement and artificial tissues, such as liver disease treatments. The $175,964 award to Hepatx Corporation will enable the creation of a simple blood test to measure the...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Faknostics LLC a $651,952 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop novel peptidic inhibitors targeting the paxillin-FAK (Focal Adhesion Kinase) interaction for the treatment of liver fibrosis. The project aims to optimize lead peptide candidates, characterize their in vitro performance, and confirm efficacy in an animal model of liver...
This $675,480 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to develop a novel therapeutic compound for treating chronic kidney disease (CKD). The awardee, Fibrotherapeutics Inc., is conducting preclinical studies to evaluate the efficacy, safety, and therapeutic index of a modified, water-soluble, orally-active peptide derived...
The U.S. Department of Health and Human Services' National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $361,400 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oncotrap Inc. The funding supports the development of a bispecific single-domain antibody targeting the chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis (NASH). The award will enable Oncotrap to generate a human version...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,391,142 to Function Therapeutics Inc. to develop small molecule PAR1 ligands as a novel treatment approach for metabolic dysfunction-associated steatohepatitis (MASH). The project aims to synthesize and evaluate novel "Parmodulin" compounds that can shift PAR1 signaling in...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $293,543 to Furanica, Inc. to develop a novel compound, FAL-113, for the treatment of nonalcoholic steatohepatitis (NASH). The project aims to determine the mechanism of action, pharmacokinetics, and pharmacological efficacy of FAL-113 in preclinical NASH models. FAL-113 is designed to simultaneously modulate...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $664,769 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oregon Health & Science University (OHSU). The grant, awarded on July 1, 2025, supports research to overcome barriers to therapeutic hepatocyte transplantation. Specifically, the project aims to genetically enhance donor hepatocytes to make them immune stealthy and expandable, enabling...
This Project Grant award of $1,508,800.00, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research conducted by The University of Texas Southwestern Medical Center (UT Southwestern) to elucidate the role of somatic genetics in chronic liver disease pathways. The research aims to 1) identify adaptive genetic pathways specific to liver disease etiologies,...
This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $350,000 to Adiutrix Therapeutics LLC to develop a novel anti-fibrotic compound platform to identify and develop first-in-class therapeutics targeting collagen prolyl-4 hydroxylase (C-P4H) activity. The goal is to treat tissue remodeling and fibrosis in underserved diseases such as idiopathic pulmonary fibrosis (IPF), scleroderma skin fibrosis, kidney fibrosis, and intestinal fibrosis...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $938,470 to the University of Massachusetts Medical School to investigate a novel adipokine that may resolve non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in mouse models. The award period runs from September 1, 2024 to June 30, 2028. The research aims...